TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Controlled Disease Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Normal Prostate Tissue Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with incomplete down-regulation/occupancy of ERs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean differences of Kupperman index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MYCAW (Measure Yourself Concerns and Wellbeing) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ESAS (Edmonton Symptom Assessment Scale) questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxidant stress level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effective closure by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety throughout the follow up duration by absence of serious incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of RVI cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Spinal sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major cardiac and cerebrovascular event (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital and ICU length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Disposition of patients including survival
Endpoint domain: Mortality/survival
Primary endpoint: Unified Huntington's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Smoking Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Continuous abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients adequately sedated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in language performance using behavioural measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in language performance using EEG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SI Joint Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with at least one adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in reported food insecurity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Diagnosis of Vaginal Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tolerability of Myfortic
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline Pre-bronchodilator FEV1 (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End-value Pre-bronchodilator FEV1 (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rett Syndrome Clinical Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Tone Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Continuation into the fourth cycle
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of Rehab system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hernia Recurrence or Reoperation
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distances for edema measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: local control at 4 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response Rate (PCRR)
Endpoint domain: Mortality/survival
Primary endpoint: Nodule allocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Disease Activity Score in 28 Joints (DAS28) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving European League Against Rheumatism (EULAR) Good Response at Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 28
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plaque vulnerability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Decisional Conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary F2-Isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of children with ASD who use medical cannabis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Cannabinoid concentrations in pediatric patients with ASD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of injection frequencies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of time of injections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Importance of factors influencing prescription of prophylaxis schedules
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Duration of Hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: The need for ICU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Coronary calcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cosmesis Evaluations
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BMI SDS or Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in hyper-responsiveness to mannitol (PD15FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of steroid-resistant acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Steep keratometry value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum keratometry value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Self-rated confidence in providing FCC
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported use of FCC skills in practice
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Clinical signs of local infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Left ventricular end-systolic diameter (ESD) > 50 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular ejection fraction (EF) < 50 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalization for heart failure symptoms
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage Change in Serum Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Screen-detected Invasive Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change in average scores of 24-hour hot flashes symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Positive Blood Culture for L. Reuteri
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Leukocyte Count on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Alanine Aminotransferase (ALT) in Female Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total beverage consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: crystalline lens tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: crystalline lens decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraventricular Hemorrhage and/or Late Onset Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Dengue symptomatic case
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Grade 3 or 4 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Terminated From Treatment Due to Suspected Adverse Drug Reaction (SADR) Attributable to the Study Medication
Endpoint domain: Adverse events/effects
Primary endpoint: No flow time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ stiffness measured by ARFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome assessed by Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of clinically significant AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically relevant abnormalities, as assessed by clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically relevant abnormalities, as assessed by vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical frailty scale validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of anterior cingulate cortex (ACC) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inhibition of functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modulation of AVP pathway effects on ACC activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under Curve (AUC) last of Tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of Tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cuff pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Copeptin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned-symptomatic visits to clinicians
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Altitude related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive test: Mini-Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scores of the scale with symptoms and signs of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in 6MWD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Congenital malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of suspected perioperative anaphylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: differences in intestinal microbiota profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in the rate of symptomatic IDH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events associated with CAR T-cell infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of successfully and unsuccessfully manufactured and infused CAR T-cell products
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lung function decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured using the visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physiologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change Per Day of Log Colony Forming Units (CFU) Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Reporting ≥Grade 3 Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of treatment schemas regarding severity of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of influenza complications requiring antibacterial drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of pulsewave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV RNA and HIV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the proportion of activated HLA-DR+CD38+CD8+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-1 RNA Response: ≥ 1 Log Decrease in Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ondansetron plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance for airway management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary exercise function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent improvement in skin induration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving ≥1 Stage Improvement in Liver Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Safety (local and systemic reactogenicity, lab tests, AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Major Molecular Response (MMR) Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time to complete intraoperative hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CHR symptom reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of External Beam Radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensorial block start time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Marker of Bone Metabolism, PINP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Bone Mineral Density, Total Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attrition Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Study Medication Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful Collection of Outcome Measures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Parent Satisfaction Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastro-intestinal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: subject reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in gamma-hydroxy-1,N(2)-propanodeoxyguanosine (gamma-OHPdG) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uptake and Retention of GE-148 (18F) Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BOLD response during an emotion regulation task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ovulation Occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ovulation Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Levels of Total Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Major Cardiovascular Cardiac Events
Endpoint domain: Mortality/survival
Primary endpoint: Severity of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of portal vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Choroidal and retinal thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete headache relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saving Inventory-Revised (SI-R)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Zung self-report Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Depression Inventory II scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in Provider Performance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Results of the ASST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Results of a cell activating assay (BHRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Results of autoantibody-test (anti-IgE and anti-FcRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Reported Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Mean Daytime Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC) of ABI-H2158
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of ABI-H2158
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes